Empirical Technologies Expands Location and Services

Empirical Technologies expands its locations and services with the launch of Empirical Europe, headquartered in Belgium. Johan Van Havermaet and Xavier Deklerck are leading the company’s European presence. Van Havermaet brings a strong background in spine and emerging technologies to the team. Deklerck has built a career in foot, ankle, and trauma products. Empirical Technologies Founder Dawn Lissy said the expansion of the company she founded has been a long-term goal.

“For years, we’ve looked to Europe as a strong and natural extension of our global footprint,” she said. “For 24 years, we’ve worked to meet the needs of clients around the world. Adding Johan and Xavier to the team means we now have the right professionals in place to better serve a critical segment of the market and our industry in the European Union.” In addition to mechanical testing and Medical Device Directive to Medical Device Regulation support, the Empirical Europe team will provide regulatory support for future MDR and FDA submissions.

The Empirical Technologies engineering team has over 50 years of combined testing experience, participates actively in several ASTM committees, and has hosted FDA reviewers for Experiential Learning Program events. Empirical Technologies’ consulting experts have a proven record of regulatory success with three Breakthrough Device Designations, more than 250 FDA 510(k) clearances, and has recently added a former director of multiple FDA divisions to our panel of experts. To continue providing our clients with top-of-the-line service, our office in the United States will work closely with our office in Belgium.

The Empirical Technologies and Empirical Europe teams are ready to assist clients with their testing and regulatory needs around so they can more quickly navigate regulatory process and get devices to market quickly and efficiently. For more information, visit EmpiricalEurope.com.

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.